EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alphamab Oncology's enterprise value is HK$1,298.0 Mil.
Alphamab Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-141.4 Mil. Therefore, Alphamab Oncology's EV-to-EBITDA for today is -9.18.
The historical rank and industry rank for Alphamab Oncology's EV-to-EBITDA or its related term are showing as below:
HKSE:09966'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.31 Med: -20.77 Max: -8.25
Current: -23.55
During the past 7 years, the highest EV-to-EBITDA of Alphamab Oncology was -8.25. The lowest was -51.31. And the median was -20.77.
HKSE:09966's EV-to-EBITDA is ranked worse than 100% of 448
companies
in the Biotechnology industry
Industry Median: 9.63
vs HKSE:09966: -23.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Alphamab Oncology EV-to-EBITDA Historical Data
The historical data trend for Alphamab Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alphamab Oncology's EV-to-EBITDA
For the Biotechnology subindustry, Alphamab Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's EV-to-EBITDA falls into.
Alphamab Oncology's current Enterprise Value is HK$1,298.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-141.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alphamab Oncology's PE Ratio for today is calculated as:
Alphamab Oncology's share price for today is HK$2.63.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.241.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Alphamab Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Alphamab Oncology (HKSE:09966) Business Description
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09966 has been successfully added to your 